Navigation Links
PARI Respiratory Releases Results of Study Comparing Nebulizers Delivering Budesonide at CHEST 2008
Date:10/28/2008

MIDLOTHIAN, Va., Oct. 28 /PRNewswire/ -- Today, PARI Respiratory Equipment presented a comparative study of three commercially available, breath-enhanced nebulizers and their in-vitro performance and delivery efficiency of budesonide inhalation suspension (Pulmicort Respules, AstraZeneca). Conclusions from the in-vitro study show that the LC Sprint Reusable Nebulizer delivered the shortest treatment times, with an average of 4.9 minutes, and had the highest respirable drug delivery rate.

"We found that drug delivery differs between commercially available nebulizers, something for clinicians to consider when contemplating whether patients receive clinically effective doses," said Lisa Cambridge, director of clinical development for PARI Respiratory Equipment, Inc. "Since patient compliance may be associated with the speed of treatment and delivery efficiency, this study highlights key differences between nebulizers."

The study compares the LC Sprint Reusable Nebulizer (PARI Respiratory Equipment), LC PLUS Reusable Nebulizer (PARI Respiratory Equipment), and Sidestream Plus reusable nebulizer (Respironics). Ms. Cambridge presented the results today at CHEST 2008, the annual meeting of the American College of Chest Physicians.

Key conclusions showed:

-- Respirable drug delivery rate (RDDR) was the highest with LC Sprint Reusable Nebulizer -- in fact, RDDR is 46% higher for LC Sprint Reusable Nebulizer compared to Sidestream Plus

-- Respirable dose is similar with LC Sprint and LC PLUS, though RDDR was 25% higher for LC Sprint Reusable Nebulizer

-- Respirable dose and RDDR for LC PLUS Reusable Nebulizer demonstrate higher delivery efficiency (33% and 39% respectively) than Sidestream Plus

-- Treatment times were shortest with LC Sprint Reusable Nebulizer (4.9 minutes)

These conclusions draw upon results from an American Thoracic Society poster (Keller M et al., 2002) that show higher respirable drug delivery rate (RDDR) indicates more drug delivery to the lower airway per minute.

About PARI Respiratory Equipment, Inc.

PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them.

Maker of the world's leading breath-enhanced reusable nebulizer, the PARI LC PLUS, and the new PARI LC Sprint nebulizer line, PARI also manufactures the award winning PARI TREK S compact compressor, Bubbles the Fish II aerosol mask, and durable PARI PRONEB Ultra II. PARI's Vortex anti-static valved holding chamber improves the aerosol deposition of metered dose inhalers (MDI's). PARI's North American headquarters is in Midlothian, VA with worldwide headquarters in Starnberg, Germany. Online at http://www.Pari.com

Additional information is available by contacting Ayars & Associates at 805-845-5682 or at 804-253-7274 x711.


'/>"/>
SOURCE PARI Respiratory Equipment, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. ILC Dover Introduces Patient Friendly Respiratory Protection for Health Care Market
2. PediatricRespiratory.org Announces a Two-Part, Live CME/CE Webcast Series on RSV and Pediatric Influenza
3. PARI Respiratory Equipment Featured on Oxygen Network
4. Burning incense increases risk of respiratory tract cancers
5. Respiratory illnesses and dog bites a concern for travelers to China for 2008 Olympics
6. National Jewish Named the #1 Respiratory Hospital for the Eleventh Year in a Row
7. Temple University Hospital Ranked Among Best in America for Respiratory Disorders by U.S. News & World Report
8. Schering-Plough and Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture
9. Melissa Biggs, Fashion Designer and Former Baywatch Actress, Teams with CSL Behring to Raise Awareness of Alpha-1 Antitrypsin Deficiency, a Commonly Misdiagnosed Respiratory Disease
10. Respiratory Therapists Offer Breath of Fresh Air During Allergy & Asthma Month
11. New agent strikes at respiratory syncytial virus replication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer ... they remain in the eye of the beholder, according to experts who offered insights ... American Journal of Managed Care. For the full issue, click here . , ...
(Date:6/26/2016)... ... ... a legally blind and certified personal trainer is helping to develop a weight loss fitness ... to fix the two major problems leading the fitness industry today:, , ... They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... , ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on ... Observer , brings up a new, often overlooked aspect of head lice: the parasite’s ability ... fumigation is not a common occurrence, but a necessary one in the event that lice ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events may suffer ... unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. To avoid ... healthy coping following a traumatic event. , Trauma sufferers tend to feel a range ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Dialysis Devices Global Market - Forecast to 2022" report ... is the treatment method for the patients with kidney failure, ... and excess fluid from the patient,s blood and thus the ... sodium, potassium and chloride in balance. Increasing ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology: